According to the latest report published by Credence Research, Inc. “Non-Invasive Prenatal Testing Market - Growth, Future Prospects and Competitive Analysis, 2016-2022,” the non-invasive prenatal testing market was valued at USD 613.0 million in 2015 and is expected to reach USD 1.939.9 million by 2022, rising at a CAGR of 17.9% from 2016 to 2022.
Market Insights
The global market for non-invasive prenatal testing (NIPT) is experiencing a double-digit growth driven by market factors such as an increase in average maternity age, growing occurrence of chromosomal abnormalities that need early and non-invasive detection. Another major factor contributing to this market's growth is the increase in healthcare spending.
Browse Full Report Originally Published by Credence Research at https://www.credenceresearch.com/report/non-invasive-prenatal-testing-market
Non-invasive prenatal testing is defined as a highly sensitive screening process that helps to detect chromosome abnormalities in the fetus during pregnancy. Some of the abnormal chromosome abilities that can be detected by NIPT are Down Syndrome, Patau Syndrome, Edwards Syndrome, and Turner Syndrome.
Among the available NIPT tests, the MaternitT21 test is the largest segment and its dominance is expected to continue through 2022. It was the first test to be approved for the detection of Trisomy 21 in 2011. Other chromosome abnormalities that could be detected with MaternitT21 include Wolf-Hirschhorn Syndrome, DiGeorge Syndrome, Langer-Giedion Syndrome, 1q36 Deletion Syndrome, and Jaconsen Syndrome. MaterniT21 uses cfDNA and parallel sequencing technology and delivers results over a 5-day period.
North America is the largest market for prenatal non-invasive testing. Emerging markets in Asia-Pacific and Latin America are growing at a significant rate of growth, due to a growing awareness of chromosome abnormalities, prevention of chromosome abnormalities, an increasing population of late maternity age, and rapid development of healthcare infrastructure. However, the most prominent market restraint is the ethical concerns associated with such tests.
The major players engaged in the global noninvasive prenatal testing market are LifeCodexx AG, Illumina, Inc., Sequenom, Inc. LABCORP, Natera, Inc. and others.
You can get the sample copy of this research by Credence Research here: https://www.credenceresearch.com/sample-request/57840
Report Scope by Segments
By Products Type
- MaterniT21 PLUS
- BambniTest
- informaSeq Prenatal Test
- Harmony Prenatal Test
- Non-invasive Fetal Trisomy (NIFTY) Test
- verifi
- PrenaTest
- Panorama Test
- VisibiliT Test
By Geography Segment
- North America (the U.S., Rest of North America)
- Europe (U.K., Germany, France, Rest of Europe)
- Asia Pacific (China, Japan, India, Rest of Asia Pacific)
- Rest of the World (the Middle East & Africa, Latin America)
No comments:
Post a Comment